Metabolic syndrome and osteoarthritis pain: common molecular mechanisms and potential therapeutic implications

Valdes, Ana M.

doi:10.1016/j.joca.2019.06.015

Cited by 27 publications

(15 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…60 Patientrelated factors such as stress, adverse life experiences, sex, gut microbiome, and comorbidities predispose to the development of central sensitisation and contribute to the pain phenotype. 7,24,93 3. The course of pain-like behaviour in rodent osteoarthritis…”

Section: The Course Of Pain In Human Osteoarthritismentioning

confidence: 99%

Peripheral pain mechanisms in osteoarthritis

Vincent

2020

Pain

View full text Add to dashboard Cite

There is a well-established historical observation that structural joint damage by plain X-ray correlates poorly with symptomatic disease in osteoarthritis (OA). This is often attributed to the inability to visualise soft-tissue pathology within the joint and the recognition of heterogeneous patient factors that drive central pain sensitisation. A major issue is the relative paucity of mechanistic studies in which molecular pathogenesis of pain is interrogated in relation to tissue pathology. Nonetheless, in recent years, three broad approaches have been deployed to attempt to address this: correlative clinical studies of peripheral and central pain outcomes using magnetic resonance imaging, where soft-tissue processes can be visualised; molecular studies on tissue from patients with OA; and careful molecular interrogation of preclinical models of OA across the disease time course. Studies have taken advantage of established clinical molecular targets such as nerve growth factor. Not only is the regulation of nerve growth factor within the joint being used to explore the relationship between tissue pathology and the origins of pain in OA, but it also provides a core model on which other molecules present within the joint can modulate the pain response. In this narrative review, how molecular and pathological tissue change relates to joint pain in OA will be discussed. Finally, a model for how tissue damage may lead to pain over the disease course will be proposed.

show abstract

Section: The Course Of Pain In Human Osteoarthritismentioning

confidence: 99%

Peripheral pain mechanisms in osteoarthritis

Vincent

2020

Pain

View full text Add to dashboard Cite

show abstract

“…A large number of studies focusing on analgesia have described the pain as the most prominent symptom of the disease and also the ability of the ECS to modulate pain in OA [ 302 ]. Mlost et al found that β-caryophyllene (a natural low-efficacy agonist of CB2r that is present in human diet) had both antinociceptive and chondroprotective effects in animals with experimentally induced osteoarthritis.…”

Section: The Endocannabinoid System and Aging-related Musculoskeletal...mentioning

confidence: 99%

The Therapeutic Potential of the Endocannabinoid System in Age-Related Diseases

et al. 2022

View full text Add to dashboard Cite

The endocannabinoid system (ECS) dynamically regulates many aspects of mammalian physiology. ECS has gained substantial interest since growing evidence suggests that it also plays a major role in several pathophysiological conditions due to its ability to modulate various underlying mechanisms. Furthermore, cannabinoids, as components of the cannabinoid system (CS), have proven beneficial effects such as anti-inflammatory, immunomodulatory, neuromodulatory, antioxidative, and cardioprotective effects. In this comprehensive review, we aimed to describe the complex interaction between CS and most common age-related diseases such as neuro-degenerative, oncological, skeletal, and cardiovascular disorders, together with the potential of various cannabinoids to ameliorate the progression of these disorders. Since chronic inflammation is postulated as the pillar of all the above-mentioned medical conditions, we also discuss in this paper the potential of CS to ameliorate aging-associated immune system dysregulation.

show abstract

“…It has been reported that molecular changes appear much earlier than apparent clinical symptoms (6). Hence, searching of biomarkers for OA has become a popular research trend (7). However, up to now, to the best of our knowledge, there have been no clinically applicable biomarkers in favor of the diagnosis, monitoring, and assessment the severity of OA owing to the heterogeneity in the pathogenesis and multiformity of clinical symptoms (8).…”

Section: Introductionmentioning

confidence: 99%

Potential Value of Matrix Metalloproteinase-13 as a Biomarker for Osteoarthritis

Xing

Tan

et al. 2021

Front. Surg.

View full text Add to dashboard Cite

Background: Emerging knowledge has highlighted the role of matrix metalloproteinase (MMP)-13 in osteoarthritis (OA); however, the suitability of MMP-13 as a biomarker for OA remains unclear. Therefore, this study aimed to assess the potential value of MMP-13 as a biomarker for OA.Methods: The study enrolled 51 patients, of which 33 had advanced varus OA and 18 did not have OA. Immunohistochemistry and western blotting analyses were performed to measure MMP-13 activity in the cartilage and subchondral bone of patients with OA. Enzyme-linked immunosorbent assay was used to measure serum MMP-13 levels in patients with or without OA. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) was used to assess the association between serum MMP-13 levels and clinical symptoms. Furthermore, the association between serum MMP-13 levels and radiological severity of OA was evaluated using the Kellgren–Lawrence (KL) grading system. Finally, we built the proportional odds logistic regression models to evaluate serum MMP-13 levels as a potential predictor for OA.Results: MMP-13 levels were significantly higher in the severe-worn cartilage of the medial tibial plateau than in the relatively intact portion of the lateral cartilage (p < 0.05). This was contrary to the findings for MMP-13 differential expression in the subchondral bone in knee OA (p < 0.05). Patients with OA had significantly higher serum MMP-13 levels compared with patients without OA. Additionally, remarkable associations among serum MMP-13 levels, WOMAC scores, and KL grading scores were found in the end-stage OA. Furthermore, the subsequent analysis suggested that serum MMP-13 level was a significant predictor for OA.Conclusion: MMP-13 is valuable for diagnosing, measuring disease severity, and predicting OA in the advanced period of the disease, suggesting that it has potential possibility as a biomarker for OA. However, the underlying mechanisms and clinical application of MMP-13 as a biomarker for OA require to be further investigated.

show abstract

Metabolic syndrome and osteoarthritis pain: common molecular mechanisms and potential therapeutic implications

Cited by 27 publications

References 16 publications

Peripheral pain mechanisms in osteoarthritis

Peripheral pain mechanisms in osteoarthritis

The Therapeutic Potential of the Endocannabinoid System in Age-Related Diseases

Potential Value of Matrix Metalloproteinase-13 as a Biomarker for Osteoarthritis

Contact Info

Product

Resources

About